DavidFrancisMcDermottMD

Associate Professor, Medicine, Harvard Medical School; Staff Physician, Hematology/Oncology, Beth Israel Deaconess Medical Center; Director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center

Join to view full profile

Dr. McDermott is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. McDermott's full profile

Already have an account?

Office
330 Brookline Ave
Boston, MA 02215
Phone+1 617-667-2100
Is this information wrong?

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
Tufts Medical CenterResidency, Internal Medicine, 1992 - 1995
Weill Cornell MedicineClass of 1992

Certifications & Licensure

MA State Medical License 1998 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 2
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2007 Sep 14
Completed
Phase 2
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Start of enrollment: 2002 Dec 01
Completed
Phase 2
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Start of enrollment: 1999 Jul 01
Completed
Phase 2
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Start of enrollment: 2009 Jan 23
Completed
Phase 2
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors Start of enrollment: 2000 Nov 01
Completed
Not Applicable
STA-9090(Ganetespib) in Metastatic Ocular Melanoma Start of enrollment: 2010 Sep 17
Completed
Phase 2
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma Start of enrollment: 2010 Feb 01
Completed
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Terminated
Phase 1, Phase 2
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2014 May 01
Completed
Phase 1
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2014 Nov 26
Terminated
Phase 2
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Start of enrollment: 2016 Jul 01
Active, not recruiting
Phase 2
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
Terminated
Phase 1, Phase 2
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma Start of enrollment: 2017 Aug 01
Active, not recruiting
Phase 2
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma Start of enrollment: 2017 Nov 27
Active, not recruiting
Phase 2
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Start of enrollment: 2020 Nov 05
Recruiting
Phase 2
ABEMA Alone or in COMBO With MK-6482 Start of enrollment: 2020 Dec 31
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, Bernard Escudier, Thomas E Hutson, Vijay Kasturi, David F McDermott, Sumanta K Pal, Camillo Porta, Bria...> ;The Oncologist. 2024 Mar 4
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
Brahmer, J., Long, G., Hamid, O., Garon, E., Herbst, R., Andre, T., Armand, P., Bajorin, D., Bellmunt, J., Burtness, B., Choueiri, T., Cohen, E., Diaz, L., Shitara, K....> ;European Journal of Cancer. 2024 Mar 1
Adjuvant immunotherapy for locally advanced renal cell carcinoma.
Alevizakos, M., McDermott, D.> ;Expert Opinion on Biological Therapy. 2023 Dec 28
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.
John M Kirkwood, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang, Sigrun Hallmeyer, David F McDermott, Hussein Tawbi, Min Che, Cho-Han Lee, Co...> ;Immunotherapy. 2024 Jan 1
1 citations
Regulation of HHLA2 expression in kidney cancer and myeloid cells.
Tomonari Shigemura, Nahuel Perrot, Zimo Huang, Rupal S Bhatt, Aseman Bagheri Sheshdeh, Nourhan El Ahmar, Fatme Ghandour, Sabina Signoretti, David F McDermott, Gordon J...> ;BMC Cancer. 2023 Oct 27
2 citations
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.
Renee Maria Saliby, Talal El Zarif, Ziad Bakouny, Valisha Shah, Wanling Xie, Ronan Flippot, Thomas Denize, M Harry Kane, Katrine N Madsen, Miriam Ficial, Laure Hirsch,...> ;Cancer Immunology Research. 2023 Aug 3
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
Bradley C Carthon, Se Eun Kim, David F McDermott, Janice P Dutcher, Maneka Puligandla, Judith Manola, Michael Pins, Michael A Carducci, Elizabeth R Plimack, Leonard J ...> ;Clinical Genitourinary Cancer. 2023 Oct 1
9 citations
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma.
Julie Stein Deutsch, Evan J Lipson, Ludmila Danilova, Suzanne L Topalian, Jaroslaw Jedrych, Ezra Baraban, Yasser Ged, Nirmish Singla, Toni K Choueiri, Saurabh Gupta, R...> ;Cell Reports. Medicine. 2023 Feb 21
1 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, Joh...> ;Journal of Clinical Oncology. 2023 Feb 10
2 citations
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
James Larkin, Mototsugu Oya, Marcella Martignoni, Fiona Thistlethwaite, Paul Nathan, Moshe C Ornstein, Thomas Powles, Kathryn E Beckermann, Arjun V Balar, David McDerm...> ;The Oncologist. 2023 Apr 6
1 citations
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Luis Meza, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Sumanta K Pal, Brian Rini> ;The Oncologist. 2023 Mar 17
18 citations
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Brian I Rini, Sabina Signoretti, Toni K Choueiri, David F McDermott, Robert J Motzer, Saby George, Thomas Powles, Frede Donskov, Scott S Tykodi, Sumanta K Pal, Saurabh...> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
2 citations
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
Zeynep B Zengin, Sumanta K Pal, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Brian Rini> ;Clinical Genitourinary Cancer. 2022 Dec 1
13 citations
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Thomas Denize, Yue Hou, Jean-Christophe Pignon, Emily Walton, Destiny J West, Gordon J Freeman, David A Braun, Catherine J Wu, Saurabh Gupta, Robert J Motzer, Michael ...> ;Clinical Cancer Research. 2022 Sep 15
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
Hollis Viray, David F McDermott, David J Einstein> ;Expert Review of Anticancer Therapy. 2022 Jul 1
13 citations
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
Elshad Hasanov, Debra Nana Yeboa, Mathew D Tucker, Todd A Swanson, Thomas Hendrix Beckham, Brian Rini, Chibawanye I Ene, Merve Hasanov, Sophie Derks, Marion Smits, Sha...> ;CA. 2022 Sep 1
105 citations
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Robert J Motzer, David F McDermott, Bernard Escudier, Mauricio Burotto, Toni K Choueiri, Hans J Hammers, Philippe Barthélémy, Elizabeth R Plimack, Camillo Porta, Saby ...> ;Cancer. 2022 Jun 1
28 citations
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni,...> ;Journal for Immunotherapy of Cancer. 2022 May 1
28 citations
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe Ornstein, M...> ;Journal of Clinical Oncology. 2022 Sep 1
52 citations
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.
Choueiri, T., Albiges, L., Atkins, M., Bakouny, Z., Bratslavsky, G., Braun, D., Haas, N., Haanen, J., Hakimi, A., Jewett, M., Jonasch, E., Kaelin, W., Kapur, P., Labak...> ;Clinical Cancer Research. 2022 Mar 1
37 citations
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
Robert J Motzer, Toni K Choueiri, David F McDermott, Thomas Powles, Yann-Alexandre Vano, Saurabh Gupta, Jin Yao, Celine Han, Ron Ammar, Simon Papillon-Cavanagh, Shruti...> ;Journal for Immunotherapy of Cancer. 2022 Mar 1
68 citations
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreate...
Robert J Motzer, Thomas Powles, Michael B Atkins, Bernard Escudier, David F McDermott, Boris Y Alekseev, Jae-Lyun Lee, Cristina Suarez, Daniil Stroyakovskiy, Ugo De Gi...> ;JAMA Oncology. 2022 Feb 1
32 citations
Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Kathleen M Mahoney, Petra Ross-Macdonald, Long Yuan, Linan Song, Eliseo Veras, Megan Wind-Rotolo, David F McDermott, F Stephen Hodi, Toni K Choueiri, Gordon J Freeman> ;Journal for Immunotherapy of Cancer. 2022 Feb 1
22 citations
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Meredith M. Regan, Opeyemi Jegede, Charlene Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, ...> ;Clinical Cancer Research. 2021 Nov 10
27 citations
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Laurence Albiges, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby G...> ;European Urology. 2021 Nov 5
Join now to see all

Journal Articles

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma
Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature

Lectures

CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcino...
2019 ASCO Annual Meeting - 6/1/2019
Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Press Mentions

Researchers Discuss Future of Cancer Therapies at 15th Annual Cancer SymposiumNovember 11th, 2022
Researchers Discuss the Future of Cancer Therapies at 15th Annual Cancer SymposiumNovember 10th, 2022
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022
Join now to see all